Full metadata record

DC Field Value Language
dc.contributor.authorElkamhawy, Ahmed-
dc.contributor.authorPark, Jung-eun-
dc.contributor.authorCho, Nam-Chul-
dc.contributor.authorSim, Taebo-
dc.contributor.authorPae, Ae Nim-
dc.contributor.authorRoh, Eun Joo-
dc.date.accessioned2024-01-20T05:03:37Z-
dc.date.available2024-01-20T05:03:37Z-
dc.date.created2021-09-05-
dc.date.issued2016-01-02-
dc.identifier.issn1475-6366-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/124516-
dc.description.abstractHerein, we report compound KST9046, a new agent possessing quinazoline-urea scaffold. Preliminary biological evaluation done by the National Cancer Institute (NCI), USA, showed a great inhibitory effect of KST9046 over the 60 cell-line tumor panel. Accordingly, it was selected for a dose-response assay; a broad spectrum antiproliferative activity with GI(50) ranging from 1.3 to 3.9 mu M was exerted. To explore a potential kinase inhibitory effect, KST9046 was applied at a single dose of 10 mu M against a kinase panel of 347 different enzymes representing >50% of the predicted human protein kinome. Interestingly, selective inhibition of 76% was observed on DDR1 kinase. Further, KST9046 showed an IC50 value of 4.38 mu M for DDR1. A molecular docking model presented KST9046 as a potential type III inhibitor for DDR1 kinase with an allosteric mode of interaction, which may offer an explanation for its selectivity. As further investigation, CYP450 assay was carried out for KST9046, it showed a promising toxicity profile against four different isoforms. Based on these findings, KST9046 can be further evaluated as a promising safe new hit for the development of broad spectrum anticancer agents with a selectivity for DDR1 kinase.-
dc.languageEnglish-
dc.publisherTAYLOR & FRANCIS LTD-
dc.subjectDISCOIDIN DOMAIN RECEPTOR-1-
dc.subjectTYROSINE KINASE-
dc.subjectCANCER-
dc.subjectINHIBITORS-
dc.subjectEXPRESSION-
dc.subjectPHOSPHORYLATION-
dc.subjectIDENTIFICATION-
dc.subjectSCREEN-
dc.titleDiscovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies-
dc.typeArticle-
dc.identifier.doi10.3109/14756366.2015.1004057-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, v.31, no.1, pp.158 - 166-
dc.citation.titleJOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY-
dc.citation.volume31-
dc.citation.number1-
dc.citation.startPage158-
dc.citation.endPage166-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000367555300020-
dc.identifier.scopusid2-s2.0-84953347439-
dc.relation.journalWebOfScienceCategoryBiochemistry & Molecular Biology-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalResearchAreaBiochemistry & Molecular Biology-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusDISCOIDIN DOMAIN RECEPTOR-1-
dc.subject.keywordPlusTYROSINE KINASE-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusINHIBITORS-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordPlusPHOSPHORYLATION-
dc.subject.keywordPlusIDENTIFICATION-
dc.subject.keywordPlusSCREEN-
dc.subject.keywordAuthorCYP450-
dc.subject.keywordAuthorDDR1 kinase inhibitor-
dc.subject.keywordAuthorkinase panel-
dc.subject.keywordAuthormolecular docking-
dc.subject.keywordAuthorNCI panel-
Appears in Collections:
KIST Article > 2016
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE